Deliverable 15. Report on biomarker and receptor-based assays in ecotoxicology
Deliverable 15. Report on biomarker and receptor-based assays in ecotoxicology
Vector-borne diseases pose global health challenges, requiring innovative drug discovery approaches. Target identification and mechanism of action (MoA) studies are essential to understand pathogen-host interactions and identify molecular targets crucial for pathogen survival, replication, or transmission. Compounds to be tested are selected properly during the early phase of drug discovery and lead development. Previous strategies and technologies are today implemented with recent discoveries. Therefore one of the main aim is to promote and strengthen innovative technologies required in the translation of leads and candidates from animal to humans and vice versa to ensure the progression of qualified leads and candidates to the end of the pre-clinical phase and de-risk studies in clinical phase 1. Ecotoxicology evaluation is essential therefore to this aim. Therefore established assays and receptor based assays are already existing and should be discussed and implemented. Marker/biomarker suggesting that in vivo the compounds is maintaining a risky or safe profile are required. Therefore the research work in the field is falling in the more general field of the identification of existing and novel assays including standardization procedures and problems.
Environmental impact of Pharmaceuticals presentation by Rolf During
COST (European Cooperation in Science and Technology) is a funding agency for research and innovation networks. The COST ACTIONS help connect research initiatives across Europe and enable scientists to grow their ideas by sharing them with their peers. This boosts their research, career and innovation.
OneHealthdrugs CA21111
Title:
One Health drugs against parasitic vector borne diseases in Europe and beyond